JPWO2020034941A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020034941A5 JPWO2020034941A5 JP2021507628A JP2021507628A JPWO2020034941A5 JP WO2020034941 A5 JPWO2020034941 A5 JP WO2020034941A5 JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021507628 A JP2021507628 A JP 2021507628A JP WO2020034941 A5 JPWO2020034941 A5 JP WO2020034941A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- variable region
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 239000000611 antibody drug conjugate Substances 0.000 claims 18
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 18
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 18
- 201000005569 Gout Diseases 0.000 claims 12
- 206010018634 Gouty Arthritis Diseases 0.000 claims 12
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 6
- 208000035690 Familial cold urticaria Diseases 0.000 claims 6
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 6
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 claims 6
- 206010072010 Hyper IgD syndrome Diseases 0.000 claims 6
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 6
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims 6
- 208000025487 periodic fever syndrome Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 102000055281 human IL1R2 Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229940126586 small molecule drug Drugs 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010003178 Arterial thrombosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 201000003274 CINCA syndrome Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000007783 downstream signaling Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 230000000737 periodic effect Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 2
- 230000002222 downregulating effect Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 1
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 claims 1
- 101710138871 Ig gamma-1 chain C region Proteins 0.000 claims 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 1
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004001 molecular interaction Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810920403.6 | 2018-08-14 | ||
| CN201810920403.6A CN110818793A (zh) | 2018-08-14 | 2018-08-14 | 抗IL-1β的抗体、其药物组合物及其用途 |
| PCT/CN2019/100343 WO2020034941A1 (zh) | 2018-08-14 | 2019-08-13 | 抗IL-1β的抗体、其药物组合物及其用途 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533770A JP2021533770A (ja) | 2021-12-09 |
| JPWO2020034941A5 true JPWO2020034941A5 (https=) | 2022-08-09 |
| JP2021533770A5 JP2021533770A5 (https=) | 2022-08-09 |
| JP7576022B2 JP7576022B2 (ja) | 2024-10-30 |
Family
ID=69524699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507628A Active JP7576022B2 (ja) | 2018-08-14 | 2019-08-13 | 抗IL-1β抗体およびその医薬組成物およびそれらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12286473B2 (https=) |
| EP (1) | EP3845560A4 (https=) |
| JP (1) | JP7576022B2 (https=) |
| KR (1) | KR20210046024A (https=) |
| CN (2) | CN110818793A (https=) |
| AU (1) | AU2019320927B2 (https=) |
| BR (1) | BR112021002794A2 (https=) |
| CA (1) | CA3108414A1 (https=) |
| EA (1) | EA202190518A1 (https=) |
| IL (1) | IL280596B2 (https=) |
| MX (2) | MX2021001778A (https=) |
| MY (1) | MY209465A (https=) |
| PH (1) | PH12021550298A1 (https=) |
| SG (1) | SG11202101435XA (https=) |
| WO (1) | WO2020034941A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN113444177A (zh) * | 2020-03-27 | 2021-09-28 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| BR112022022089A2 (pt) * | 2020-05-22 | 2022-12-13 | R Pharm Overseas Inc | Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss |
| WO2021257539A1 (en) * | 2020-06-16 | 2021-12-23 | Academia Sinica | ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF |
| CN116063488B (zh) * | 2022-10-21 | 2025-09-30 | 杭州靶向食品科技有限公司 | 一种单克隆抗体及其治疗痛风的用途 |
| CN116688130A (zh) * | 2023-06-08 | 2023-09-05 | 桂林医学院附属医院 | 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用 |
| KR102844307B1 (ko) | 2023-09-26 | 2025-08-07 | 사회복지법인 삼성생명공익재단 | 비흡연자의 조기 폐암 진단용 바이오마커 및 이의 용도 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| CA2824167C (en) * | 2002-09-06 | 2018-09-25 | Amgen Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| DK1899378T3 (da) * | 2005-06-21 | 2010-02-01 | Xoma Technology Ltd | IL-1 beta-bindende antistoffer og fragmenter deraf |
| EP2468301A1 (en) | 2007-05-29 | 2012-06-27 | Novartis AG | New indications for anti-IL-1-beta therapy |
| IN2012DN02634A (https=) | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| JP5866130B2 (ja) * | 2010-09-10 | 2016-02-17 | アペクシジェン, インコーポレイテッド | 抗IL−1β抗体およびその使用方法 |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| JP5918275B2 (ja) | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| CA2888583C (en) | 2012-11-05 | 2022-03-29 | Delenex Therapeutics Ag | Binding members to il-1 beta |
| CN105324396A (zh) * | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| CN103554264B (zh) * | 2013-11-05 | 2015-08-12 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL-1β和IL-17A的双特异性抗体及其应用 |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CN107474139B (zh) * | 2017-06-23 | 2021-04-27 | 苏州博聚华生物医药科技有限公司 | 一种靶向人肿瘤干细胞的单克隆抗体及其应用 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN113444177A (zh) * | 2020-03-27 | 2021-09-28 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
-
2018
- 2018-08-14 CN CN201810920403.6A patent/CN110818793A/zh active Pending
-
2019
- 2019-08-13 WO PCT/CN2019/100343 patent/WO2020034941A1/zh not_active Ceased
- 2019-08-13 BR BR112021002794-7A patent/BR112021002794A2/pt unknown
- 2019-08-13 IL IL280596A patent/IL280596B2/en unknown
- 2019-08-13 MY MYPI2021000751A patent/MY209465A/en unknown
- 2019-08-13 EP EP19849700.0A patent/EP3845560A4/en active Pending
- 2019-08-13 EA EA202190518A patent/EA202190518A1/ru unknown
- 2019-08-13 CN CN201980053246.6A patent/CN112654640B/zh active Active
- 2019-08-13 JP JP2021507628A patent/JP7576022B2/ja active Active
- 2019-08-13 KR KR1020217007489A patent/KR20210046024A/ko active Pending
- 2019-08-13 SG SG11202101435XA patent/SG11202101435XA/en unknown
- 2019-08-13 US US17/267,115 patent/US12286473B2/en active Active
- 2019-08-13 MX MX2021001778A patent/MX2021001778A/es unknown
- 2019-08-13 CA CA3108414A patent/CA3108414A1/en active Pending
- 2019-08-13 AU AU2019320927A patent/AU2019320927B2/en active Active
-
2021
- 2021-02-10 PH PH12021550298A patent/PH12021550298A1/en unknown
- 2021-02-12 MX MX2025005169A patent/MX2025005169A/es unknown
-
2025
- 2025-03-26 US US19/090,745 patent/US20260035455A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533770A5 (https=) | ||
| CN108290948B (zh) | 抗-cd47抗体及使用方法 | |
| JP5818804B2 (ja) | ヒトil−22raに対するヒト化抗体 | |
| EP1786918A2 (en) | Novel tetravalent bispecific antibody | |
| US20200277366A1 (en) | MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| CN115785268B (zh) | 抗cd47抗体及其用途 | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| JP2025026839A (ja) | Muc18に特異的な抗体 | |
| CA3183462A1 (en) | 4-1bb-binding protein and use thereof | |
| US20230295324A1 (en) | Ox40-targeted antibody, and preparation method therefor and application thereof | |
| AU2020400801B2 (en) | Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof | |
| JPWO2020034941A5 (https=) | ||
| JP7036471B2 (ja) | デスレセプター4及びデスレセプター5に結合する非常に強力な抗体 | |
| WO2023134767A1 (zh) | 一种靶向IL-18Rβ的抗体及其应用 | |
| CA3089649A1 (en) | Anti-tip-1 antibodies and uses thereof | |
| CN121013865A (zh) | 抗cd180结合分子及其用途 | |
| CA3221903A1 (en) | Anti-upar antibodies and uses thereof | |
| CN120554511B (zh) | 一种抗钙粘蛋白-17的抗体及其抗体药物偶联物 | |
| JP2025504012A (ja) | 抗btla抗体および癌治療におけるその使用 | |
| RU2024109579A (ru) | Анти-LAG3 антитело, фармацевтическая композиция и применение | |
| KR20250152067A (ko) | 항-il2ra 항체 및 이의 용도 | |
| KR20250167608A (ko) | 항-bdca2 항체 | |
| WO2025172588A1 (en) | Bispecific constructs directed against fap and ltbr | |
| CN120322458A (zh) | Cd38单克隆抗体及其应用 |